Direct-to-Consumer Prescription Drug Advertising in the United States: A Narrative Review of Clinical, Public-Health, Ethical, and Economic Implications

Abstract

Background. Direct-to-consumer advertising (DTCA) of prescription drugs is permitted in only two high-income countries — the United States and New Zealand — and represents a multi-billion-dollar component of the U.S. health-care environment. Recent policy debates and proposals have focused on whether and how to tighten regulatory oversight of DTCA, particularly as digital and social-media promotion have grown. Approach. This narrative review and policy analysis synthesizes peer-reviewed empirical research, government reports, and primary regulatory documents addressing DTCA’s effects on patient and clinician behavior, public health, ethics, and the health-care economy. Key Findings. Across multiple study designs, DTCA increases information seeking, patient requests, and prescribing of advertised products, with measurable effects on diagnosis rates and class-level utilization. Patients who specifically request a DTCA-promoted drug receive a prescription substantially more often than those who do not. Higher promotional spending tends to be directed toward branded products with comparatively low added clinical benefit. Modeling analyses suggest that meaningful changes in DTCA spending translate into measurable, though modest, changes in national prescription drug spending. Conclusions. DTCA is a clinical, ethical, public-health, and economic phenomenon, not merely a marketing practice. Clinicians can mitigate harms through structured response to ad-driven requests and shared decision-making. Health systems can integrate DTCA awareness into clinician education and decision support. Policymakers continue to weigh a range of options, including stricter risk-presentation standards, broader oversight of digital promotion, and fiscal levers such as limits on tax deductibility for DTCA expenditures.